Time-Restricted Salutary Effects of Blood Flow Restoration on Venous Thrombosis and Vein Wall Injury in Mouse and Human Subjects
Up to 50% of patients with proximal deep vein thrombosis (DVT) will develop the postthrombotic syndrome characterized by limb swelling and discomfort, hyperpigmentation, skin ulcers, and impaired quality of life. Although catheter-based interventions enabling the restoration of blood flow (RBF) have...
Uložené v:
| Vydané v: | Circulation (New York, N.Y.) Ročník 143; číslo 12; s. 1224 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
23.03.2021
|
| Predmet: | |
| ISSN: | 1524-4539, 1524-4539 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Up to 50% of patients with proximal deep vein thrombosis (DVT) will develop the postthrombotic syndrome characterized by limb swelling and discomfort, hyperpigmentation, skin ulcers, and impaired quality of life. Although catheter-based interventions enabling the restoration of blood flow (RBF) have demonstrated little benefit on postthrombotic syndrome, the impact on the acuity of the thrombus and mechanisms underlying this finding remain obscure. In experimental and clinical studies, we examined whether RBF has a restricted time window for improving DVT resolution.
First, experimental stasis DVT was generated in C57/BL6 mice (n=291) by inferior vena cava ligation. To promote RBF, mice underwent mechanical deligation with or without intravenous recombinant tissue plasminogen activator administered 2 days after deligation. RBF was assessed over time by ultrasonography and intravital microscopy. Resected thrombosed inferior vena cava specimens underwent thrombus and vein wall histological and gene expression assays. Next, in a clinical study, we conducted a post hoc analysis of the ATTRACT (Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis) pharmacomechanical catheter-directed thrombolysis (PCDT) trial (NCT00790335) to assess the effects of PCDT on Venous Insufficiency Epidemiological and Economic Study quality-of-life and Villalta scores for specific symptom-onset-to-randomization timeframes.
Mice that developed RBF by day 4, but not later, exhibited reduced day 8 thrombus burden parameters and reduced day 8 vein wall fibrosis and inflammation, compared with controls. In mice without RBF, recombinant tissue plasminogen activator administered at day 4, but not later, reduced day 8 thrombus burden and vein wall fibrosis. It is notable that, in mice already exhibiting RBF by day 4, recombinant tissue plasminogen activator administration did not further reduce thrombus burden or vein wall fibrosis. In the ATTRACT trial, patients receiving PCDT in an intermediate symptom-onset-to-randomization timeframe of 4 to 8 days demonstrated maximal benefits in Venous Insufficiency Epidemiological and Economic Study quality-of-life and Villalta scores (between-group difference=8.41 and 1.68, respectively,
<0.001 versus patients not receiving PCDT). PCDT did not improve postthrombotic syndrome scores for patients having a symptom-onset-to-randomization time of <4 days or >8 days.
Taken together, these data illustrate that, within a restricted therapeutic window, RBF improves DVT resolution, and PCDT may improve clinical outcomes. Further studies are warranted to examine the value of time-restricted RBF strategies to reduce postthrombotic syndrome in patients with DVT. |
|---|---|
| AbstractList | Up to 50% of patients with proximal deep vein thrombosis (DVT) will develop the postthrombotic syndrome characterized by limb swelling and discomfort, hyperpigmentation, skin ulcers, and impaired quality of life. Although catheter-based interventions enabling the restoration of blood flow (RBF) have demonstrated little benefit on postthrombotic syndrome, the impact on the acuity of the thrombus and mechanisms underlying this finding remain obscure. In experimental and clinical studies, we examined whether RBF has a restricted time window for improving DVT resolution.BACKGROUNDUp to 50% of patients with proximal deep vein thrombosis (DVT) will develop the postthrombotic syndrome characterized by limb swelling and discomfort, hyperpigmentation, skin ulcers, and impaired quality of life. Although catheter-based interventions enabling the restoration of blood flow (RBF) have demonstrated little benefit on postthrombotic syndrome, the impact on the acuity of the thrombus and mechanisms underlying this finding remain obscure. In experimental and clinical studies, we examined whether RBF has a restricted time window for improving DVT resolution.First, experimental stasis DVT was generated in C57/BL6 mice (n=291) by inferior vena cava ligation. To promote RBF, mice underwent mechanical deligation with or without intravenous recombinant tissue plasminogen activator administered 2 days after deligation. RBF was assessed over time by ultrasonography and intravital microscopy. Resected thrombosed inferior vena cava specimens underwent thrombus and vein wall histological and gene expression assays. Next, in a clinical study, we conducted a post hoc analysis of the ATTRACT (Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis) pharmacomechanical catheter-directed thrombolysis (PCDT) trial (NCT00790335) to assess the effects of PCDT on Venous Insufficiency Epidemiological and Economic Study quality-of-life and Villalta scores for specific symptom-onset-to-randomization timeframes.METHODSFirst, experimental stasis DVT was generated in C57/BL6 mice (n=291) by inferior vena cava ligation. To promote RBF, mice underwent mechanical deligation with or without intravenous recombinant tissue plasminogen activator administered 2 days after deligation. RBF was assessed over time by ultrasonography and intravital microscopy. Resected thrombosed inferior vena cava specimens underwent thrombus and vein wall histological and gene expression assays. Next, in a clinical study, we conducted a post hoc analysis of the ATTRACT (Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis) pharmacomechanical catheter-directed thrombolysis (PCDT) trial (NCT00790335) to assess the effects of PCDT on Venous Insufficiency Epidemiological and Economic Study quality-of-life and Villalta scores for specific symptom-onset-to-randomization timeframes.Mice that developed RBF by day 4, but not later, exhibited reduced day 8 thrombus burden parameters and reduced day 8 vein wall fibrosis and inflammation, compared with controls. In mice without RBF, recombinant tissue plasminogen activator administered at day 4, but not later, reduced day 8 thrombus burden and vein wall fibrosis. It is notable that, in mice already exhibiting RBF by day 4, recombinant tissue plasminogen activator administration did not further reduce thrombus burden or vein wall fibrosis. In the ATTRACT trial, patients receiving PCDT in an intermediate symptom-onset-to-randomization timeframe of 4 to 8 days demonstrated maximal benefits in Venous Insufficiency Epidemiological and Economic Study quality-of-life and Villalta scores (between-group difference=8.41 and 1.68, respectively, P<0.001 versus patients not receiving PCDT). PCDT did not improve postthrombotic syndrome scores for patients having a symptom-onset-to-randomization time of <4 days or >8 days.RESULTSMice that developed RBF by day 4, but not later, exhibited reduced day 8 thrombus burden parameters and reduced day 8 vein wall fibrosis and inflammation, compared with controls. In mice without RBF, recombinant tissue plasminogen activator administered at day 4, but not later, reduced day 8 thrombus burden and vein wall fibrosis. It is notable that, in mice already exhibiting RBF by day 4, recombinant tissue plasminogen activator administration did not further reduce thrombus burden or vein wall fibrosis. In the ATTRACT trial, patients receiving PCDT in an intermediate symptom-onset-to-randomization timeframe of 4 to 8 days demonstrated maximal benefits in Venous Insufficiency Epidemiological and Economic Study quality-of-life and Villalta scores (between-group difference=8.41 and 1.68, respectively, P<0.001 versus patients not receiving PCDT). PCDT did not improve postthrombotic syndrome scores for patients having a symptom-onset-to-randomization time of <4 days or >8 days.Taken together, these data illustrate that, within a restricted therapeutic window, RBF improves DVT resolution, and PCDT may improve clinical outcomes. Further studies are warranted to examine the value of time-restricted RBF strategies to reduce postthrombotic syndrome in patients with DVT.CONCLUSIONSTaken together, these data illustrate that, within a restricted therapeutic window, RBF improves DVT resolution, and PCDT may improve clinical outcomes. Further studies are warranted to examine the value of time-restricted RBF strategies to reduce postthrombotic syndrome in patients with DVT. Up to 50% of patients with proximal deep vein thrombosis (DVT) will develop the postthrombotic syndrome characterized by limb swelling and discomfort, hyperpigmentation, skin ulcers, and impaired quality of life. Although catheter-based interventions enabling the restoration of blood flow (RBF) have demonstrated little benefit on postthrombotic syndrome, the impact on the acuity of the thrombus and mechanisms underlying this finding remain obscure. In experimental and clinical studies, we examined whether RBF has a restricted time window for improving DVT resolution. First, experimental stasis DVT was generated in C57/BL6 mice (n=291) by inferior vena cava ligation. To promote RBF, mice underwent mechanical deligation with or without intravenous recombinant tissue plasminogen activator administered 2 days after deligation. RBF was assessed over time by ultrasonography and intravital microscopy. Resected thrombosed inferior vena cava specimens underwent thrombus and vein wall histological and gene expression assays. Next, in a clinical study, we conducted a post hoc analysis of the ATTRACT (Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis) pharmacomechanical catheter-directed thrombolysis (PCDT) trial (NCT00790335) to assess the effects of PCDT on Venous Insufficiency Epidemiological and Economic Study quality-of-life and Villalta scores for specific symptom-onset-to-randomization timeframes. Mice that developed RBF by day 4, but not later, exhibited reduced day 8 thrombus burden parameters and reduced day 8 vein wall fibrosis and inflammation, compared with controls. In mice without RBF, recombinant tissue plasminogen activator administered at day 4, but not later, reduced day 8 thrombus burden and vein wall fibrosis. It is notable that, in mice already exhibiting RBF by day 4, recombinant tissue plasminogen activator administration did not further reduce thrombus burden or vein wall fibrosis. In the ATTRACT trial, patients receiving PCDT in an intermediate symptom-onset-to-randomization timeframe of 4 to 8 days demonstrated maximal benefits in Venous Insufficiency Epidemiological and Economic Study quality-of-life and Villalta scores (between-group difference=8.41 and 1.68, respectively, <0.001 versus patients not receiving PCDT). PCDT did not improve postthrombotic syndrome scores for patients having a symptom-onset-to-randomization time of <4 days or >8 days. Taken together, these data illustrate that, within a restricted therapeutic window, RBF improves DVT resolution, and PCDT may improve clinical outcomes. Further studies are warranted to examine the value of time-restricted RBF strategies to reduce postthrombotic syndrome in patients with DVT. |
| Author | Libby, Peter Weinberg, Ido Lee, Hang Tawakol, Ahmed Henke, Peter K Wang, Lang Kessinger, Chase W Jaff, Michael R Li, Wenzhu Jaffer, Farouc A Reed, Guy L Orii, Makoto |
| Author_xml | – sequence: 1 givenname: Wenzhu surname: Li fullname: Li, Wenzhu organization: Now with Department of Geriatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (W.L.) – sequence: 2 givenname: Chase W surname: Kessinger fullname: Kessinger, Chase W organization: Masonic Medical Research Institute, Utica, NY (C.W.K.) – sequence: 3 givenname: Makoto surname: Orii fullname: Orii, Makoto organization: Department of Radiology, Iwate Medical University Hospital, Morioka, Japan (M.O.) – sequence: 4 givenname: Hang surname: Lee fullname: Lee, Hang organization: Biostatistics Center (H.L.), Massachusetts General Hospital, Harvard Medical School, Boston – sequence: 5 givenname: Lang surname: Wang fullname: Wang, Lang organization: Cardiovascular Division, Hubei Renmin Hospital, Wuhan University, China (L.W.) – sequence: 6 givenname: Ido surname: Weinberg fullname: Weinberg, Ido organization: Vascular Medicine (I.W.), Massachusetts General Hospital, Harvard Medical School, Boston – sequence: 7 givenname: Michael R surname: Jaff fullname: Jaff, Michael R organization: Department of Medicine (M.R.J.), Massachusetts General Hospital, Harvard Medical School, Boston – sequence: 8 givenname: Guy L surname: Reed fullname: Reed, Guy L organization: Department of Medicine, University of Arizona, College of Medicine, Phoenix (G.L.R.) – sequence: 9 givenname: Peter surname: Libby fullname: Libby, Peter organization: Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston (P.L.) – sequence: 10 givenname: Ahmed surname: Tawakol fullname: Tawakol, Ahmed organization: Cardiovascular Research Center, Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston (W.L., C.W.K., M.O., L.W., A.T., F.A.J.) – sequence: 11 givenname: Peter K surname: Henke fullname: Henke, Peter K organization: Section of Vascular Surgery, Department of Surgery, University of Michigan, Ann Arbor (P.K.H.) – sequence: 12 givenname: Farouc A surname: Jaffer fullname: Jaffer, Farouc A organization: Cardiovascular Research Center, Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston (W.L., C.W.K., M.O., L.W., A.T., F.A.J.) |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33445952$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkF1LwzAUhoNMnJv-BYl33nQmadM0l3NsrjAdbJ1elrRJsKNNZtMi3vnTzXSCcOB8Pbyc847AwFijALjFaIJxjO9n6Wa2W02zdP08XU4nmKAJijji8Rm4xJREQURDPvhXD8HIuT1CKA4ZvQDDMIwiyim5BF9Z1ahgo1zXVmWnJNyKuu9E-wnnWquyc9Bq-FBbK-Gith_wSNpWdJU10MeLMrZ3MHtrbVNYVzkojPTTysBXUdcwNfvea_n2yXPqZ7vsG2Hgti_2R_0rcK5F7dT1KY_BbjHPZstgtX5MZ9NVUNIwigNCFJOYqhJrJonknMS0ZKwsFI54IeMQaVQSgRKEE0kFiTXCWmgeqlAizDgZg7tf3UNr33v_Rd5UrlR1LYzyp-UkYglNGGexR29OaF80SuaHtmq8I_mfa-QboPp0KQ |
| CitedBy_id | crossref_primary_10_1177_1358863X211042930 crossref_primary_10_1177_1358863X231165105 crossref_primary_10_3390_biomedicines12010200 crossref_primary_10_1016_j_jvsv_2021_07_020 crossref_primary_10_1016_j_bvth_2024_100013 crossref_primary_10_1016_j_rpth_2023_102268 crossref_primary_10_1002_acm2_14048 crossref_primary_10_1007_s12185_023_03651_6 crossref_primary_10_1038_s42003_023_04492_z crossref_primary_10_1111_jcmm_17472 crossref_primary_10_1161_CIRCULATIONAHA_124_069728 crossref_primary_10_1111_jth_15510 crossref_primary_10_1161_JAHA_122_028056 crossref_primary_10_1161_CIRCRESAHA_125_326540 crossref_primary_10_1016_j_jtha_2024_09_012 crossref_primary_10_1161_CIRCULATIONAHA_120_052451 crossref_primary_10_1016_j_jvir_2021_10_036 crossref_primary_10_1016_j_bvth_2024_100029 crossref_primary_10_1016_j_carbpol_2024_122058 crossref_primary_10_1161_JAHA_121_021659 crossref_primary_10_1007_s10439_024_03609_7 crossref_primary_10_1038_s41598_024_58734_z crossref_primary_10_1055_a_1580_2981 crossref_primary_10_1177_02683555241271914 crossref_primary_10_1161_CIR_0000000000001330 crossref_primary_10_1177_1358863X251324911 crossref_primary_10_1155_2022_6909764 crossref_primary_10_1186_s12959_023_00472_9 crossref_primary_10_1016_j_jacbts_2024_12_004 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1161/CIRCULATIONAHA.120.049096 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1524-4539 |
| ExternalDocumentID | 33445952 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NHLBI NIH HHS grantid: R01 HL137913 – fundername: NINDS NIH HHS grantid: R01 NS089707 – fundername: NHLBI NIH HHS grantid: R01 HL132988 – fundername: NHLBI NIH HHS grantid: R41 HL092750 – fundername: NHLBI NIH HHS grantid: R01 HL134892 – fundername: NHLBI NIH HHS grantid: R01 HL150538 – fundername: NHLBI NIH HHS grantid: R01 HL144550 |
| GroupedDBID | --- .-D .3C .XZ .Z2 01R 0R~ 0ZK 18M 1J1 29B 2FS 2WC 354 40H 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 6PF 71W 77Y 7O~ AAAAV AAAXR AAFWJ AAGIX AAHPQ AAIQE AAJCS AAMOA AAMTA AAQKA AARTV AASCR AASOK AASXQ AAUEB AAWTL AAXQO ABASU ABBUW ABDIG ABJNI ABOCM ABPMR ABPXF ABQRW ABVCZ ABXVJ ABXYN ABZAD ABZZY ACDDN ACDOF ACEWG ACGFO ACGFS ACILI ACLDA ACOAL ACRKK ACWDW ACWRI ACXJB ACXNZ ACZKN ADBBV ADCYY ADGGA ADHPY AE3 AE6 AEBDS AENEX AFBFQ AFCHL AFDTB AFEXH AFMBP AFNMH AFSOK AFUWQ AGINI AHMBA AHOMT AHQNM AHQVU AHRYX AHVBC AIJEX AINUH AJCLO AJIOK AJNWD AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC ASPBG AVWKF AYCSE AZFZN BAWUL BOYCO BQLVK BYPQX C45 CGR CS3 CUY CVF DIK DIWNM DU5 E3Z EBS ECM EEVPB EIF ERAAH EX3 F2K F2L F2M F2N F5P FCALG GNXGY GQDEL GX1 H0~ HLJTE HZ~ IKREB IKYAY IN~ IPNFZ JF9 JG8 JK3 K-A K-F K8S KD2 KMI KQ8 L-C L7B N9A NPM N~7 N~B O9- OAG OAH OBH OCB ODMTH OGEVE OHH OHYEH OK1 OL1 OLB OLG OLH OLU OLV OLY OLZ OPUJH OVD OVDNE OVIDH OVLEI OVOZU OWBYB OWU OWV OWW OWX OWY OWZ OXXIT P2P PQQKQ RAH RIG RLZ S4R S4S T8P TEORI TR2 TSPGW UPT V2I VVN W2D W3M W8F WH7 WOQ WOW X3V X3W XXN XYM YFH YOC YSK YYM YZZ ZFV ZY1 ~H1 7X8 ABUFD ACBKD ADKSD ADSXY |
| ID | FETCH-LOGICAL-c5346-22e7d15ec1f7d2d99265c77cbe149bd630f0c2a08018d5a26f01faf93e3d01792 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 28 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=00003017-202103230-00006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1524-4539 |
| IngestDate | Sun Nov 09 12:29:45 EST 2025 Mon Jul 21 05:51:02 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Keywords | fibrinolysis postthrombotic syndrome inflammation thrombectomy venous thrombosis |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5346-22e7d15ec1f7d2d99265c77cbe149bd630f0c2a08018d5a26f01faf93e3d01792 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.120.049096 |
| PMID | 33445952 |
| PQID | 2478587976 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2478587976 pubmed_primary_33445952 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-March-23 |
| PublicationDateYYYYMMDD | 2021-03-23 |
| PublicationDate_xml | – month: 03 year: 2021 text: 2021-March-23 day: 23 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Circulation (New York, N.Y.) |
| PublicationTitleAlternate | Circulation |
| PublicationYear | 2021 |
| References | 33750208 - Circulation. 2021 Mar 23;143(12):1239-1241. doi: 10.1161/CIRCULATIONAHA.120.052451 |
| References_xml | – reference: 33750208 - Circulation. 2021 Mar 23;143(12):1239-1241. doi: 10.1161/CIRCULATIONAHA.120.052451 |
| SSID | ssj0006375 |
| Score | 2.5059283 |
| Snippet | Up to 50% of patients with proximal deep vein thrombosis (DVT) will develop the postthrombotic syndrome characterized by limb swelling and discomfort,... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1224 |
| SubjectTerms | Animals Blood Circulation - physiology Endothelium, Vascular - pathology Female Humans Male Mice Quality of Life Treatment Outcome Veins - pathology Venous Thrombosis - physiopathology |
| Title | Time-Restricted Salutary Effects of Blood Flow Restoration on Venous Thrombosis and Vein Wall Injury in Mouse and Human Subjects |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33445952 https://www.proquest.com/docview/2478587976 |
| Volume | 143 |
| WOSCitedRecordID | wos00003017-202103230-00006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bS9xAFB5sLeKLWu3FWssRpG-jyVwymadiFxcFd5H1wr4tk7nglproplh860_vmUnEp4JQCIHcYMicnPPNd06-Q8g-s5aXUhvKdDBUYECgCI48dSzwqspNYIlwuz5T43E5nerznnBr-7LKJ5-YHLVrbOTID5lQpSwVRs9vd_c0do2K2dW-hcYrsswRykSrVtNntfCCJ6FdDFGCCsn1CtlLTqLIDwenk8HVWSc4exIZwewg5sB08W-kmSLOcP1_x7pB1nqsCUedcbwlS77eJFtHNa6zbx_hK6Tqz0Srb5KVUZ9k3yJ_4m8hdOJjRw-LgBQuDJqnWTxCJ3XcQhPgeyx4h-HP5jdMUnOaNMOA23VSfYXLm0VzWzXtvAVTOzw7ryGy9nBa_8B5BDwc4X0-XU2pBEAnFlmh9h25Gh5fDk5o36iBWslFQRnzyuXS2zwox5zWrJBWKVt5XH9VruBZyCwzCE7z0knDipDlwQTNPXfRI7D35HXd1P4jgVBWCiGORZwYhArSaBM137nITMC1ldome0-vfIYfQsxumNrjcGfPL32bfOjmbXbXKXbMOBdCask-veDpHbLKYt1Kxinjn8lyQDfgd8kb-_Br3i6-JAvD_fh89BciZdrG |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Time-Restricted+Salutary+Effects+of+Blood+Flow+Restoration+on+Venous+Thrombosis+and+Vein+Wall+Injury+in+Mouse+and+Human+Subjects&rft.jtitle=Circulation+%28New+York%2C+N.Y.%29&rft.au=Li%2C+Wenzhu&rft.au=Kessinger%2C+Chase+W&rft.au=Orii%2C+Makoto&rft.au=Lee%2C+Hang&rft.date=2021-03-23&rft.issn=1524-4539&rft.eissn=1524-4539&rft.volume=143&rft.issue=12&rft.spage=1224&rft_id=info:doi/10.1161%2FCIRCULATIONAHA.120.049096&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1524-4539&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1524-4539&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1524-4539&client=summon |